{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:31:35Z","timestamp":1786984295651,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T00:00:00Z","timestamp":1529625600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Allergology International"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.alit.2018.06.002","type":"journal-article","created":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T10:57:58Z","timestamp":1531911478000},"page":"59-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy and safety of rupatadine in Japanese adult and adolescent patients with chronic spontaneous urticaria: A double-blind, randomized, multicenter, placebo-controlled clinical trial"],"prefix":"10.1016","volume":"68","author":[{"given":"Michihiro","family":"Hide","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamasa","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.alit.2018.06.002_bib1","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/all.13397","article-title":"The EAACI\/GA2 LEN\/EDF\/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2017 revision and update","volume":"73","author":"Zuberbier","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2018.06.002_bib2","series-title":"WAO White Book on Allergy: Update 2013","author":"Pawankar","year":"2013"},{"key":"10.1016\/j.alit.2018.06.002_bib3","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.alit.2018.06.002_bib4","first-page":"59","article-title":"Pathogenesis of chronic urticaria: an overview","volume":"12","author":"Jain","year":"2014","journal-title":"Dermatol Res Pract"},{"key":"10.1016\/j.alit.2018.06.002_bib5","doi-asserted-by":"crossref","first-page":"4123694","DOI":"10.1155\/2017\/4123694","article-title":"Mediators of inflammation and angiogenesis in chronic spontaneous urticaria: are they potential biomarkers of the disease?","volume":"2017","author":"Puxeddu","year":"2017","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.alit.2018.06.002_bib6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2332\/allergolint.12-RAI-0497","article-title":"Japanese guidelines for diagnosis and treatment of urticaria in comparison with other countries","volume":"61","author":"Hide","year":"2012","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2018.06.002_bib7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1398-9995.2010.02496.x","article-title":"Unmet clinical needs in chronic spontaneous urticaria: a GA2LEN task force report","volume":"66","author":"Maurer","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2018.06.002_bib8","first-page":"134","volume":"55","author":"Tanaka","year":"2006","journal-title":"Arerugi"},{"key":"10.1016\/j.alit.2018.06.002_bib9","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.mpaic.2014.02.011","article-title":"Histamine and antihistamines","volume":"15","author":"Mahdy","year":"2014","journal-title":"Anaesth Intensive Care Med"},{"key":"10.1016\/j.alit.2018.06.002_bib10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40629-014-0011-7","article-title":"Rupatadine: efficacy and safety of a non-sedating antihistamine with PAF-antagonist effects","volume":"23","author":"Shamizadeh","year":"2014","journal-title":"Allergo J Int"},{"key":"10.1016\/j.alit.2018.06.002_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0929-7855(97)00574-9","article-title":"A\u00a0pharmacophore for high affinity PAF antagonists. II. Hydrophobicity study using the molecular lipophilicity potential","volume":"16","author":"Le Solleu","year":"1997","journal-title":"J\u00a0Lipid Mediat Cell Signal"},{"key":"10.1016\/j.alit.2018.06.002_bib12","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.alit.2018.06.002_bib13","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.2336\/nishinihonhifu.45.1042","volume":"45","author":"Oxatomide Clinical Research Group","year":"1983","journal-title":"Nishi Nihon Hifuka [Nishinihon J Dermatol]"},{"key":"10.1016\/j.alit.2018.06.002_bib14","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1046\/j.1365-2133.2003.05293.x","article-title":"Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study","volume":"148","author":"Kawashima","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2018.06.002_bib15","first-page":"2031","volume":"120","author":"Iwamoto","year":"2010","journal-title":"Nihon Hifuka Gakkai Zasshi [Jpn J Dermatol]"},{"key":"10.1016\/j.alit.2018.06.002_bib16","unstructured":"International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) MedDRA\u00ae the Medical Dictionary for Regulatory Activities. A registered trademark of the international federation of pharmaceutical manufacturers and associations (IFPMA); Chantilly, VA: Northrop Grumman MSSO (distributors). Available at: http:\/\/www.meddra.org\/. Accessed 12 July 2018."},{"key":"10.1016\/j.alit.2018.06.002_bib17","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_40. Accessed 12 July 2018"},{"key":"10.1016\/j.alit.2018.06.002_bib18","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2340\/00015555-1246","article-title":"Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus","volume":"92","author":"Phan","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.alit.2018.06.002_bib19","first-page":"223","article-title":"Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study","volume":"17","author":"Dubertret","year":"2007","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.alit.2018.06.002_bib20","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1398-9995.2007.01330.x","article-title":"Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicentre study","volume":"62","author":"Gim\u00e9nez-Arnau","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2018.06.002_bib21","unstructured":"Rupatadine 10 mg Tablets: summary of product characteristics. Electronic Medicines Compendium. Available at: http:\/\/www.medicines.org.uk\/emc. Accessed 12 July 2018."},{"key":"10.1016\/j.alit.2018.06.002_bib22","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s13555-015-0089-y","article-title":"Rupatadine in established treatment schemes improves chronic spontaneous urticaria symptoms and patients' quality of life: a prospective, non-interventional trial","volume":"5","author":"Metz","year":"2015","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"Suppl 87","key":"10.1016\/j.alit.2018.06.002_bib23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1398-9995.2008.01640.x","article-title":"Rupatadine in allergic rhinitis and chronic urticaria","volume":"63","author":"Mullol","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2018.06.002_bib24","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1517\/14656566.7.14.1989","article-title":"Rupatadine: pharmacological profile and its use in the treatment of allergic disorders","volume":"7","author":"Picado","year":"2006","journal-title":"Expert Opin Pharmacother"}],"container-title":["Allergology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893018300832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893018300832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:08:46Z","timestamp":1761156526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1323893018300832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S1323893018300832"],"URL":"https:\/\/doi.org\/10.1016\/j.alit.2018.06.002","relation":{},"ISSN":["1323-8930"],"issn-type":[{"value":"1323-8930","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of rupatadine in Japanese adult and adolescent patients with chronic spontaneous urticaria: A double-blind, randomized, multicenter, placebo-controlled clinical trial","name":"articletitle","label":"Article Title"},{"value":"Allergology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.alit.2018.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Japanese Society of Allergology. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}